Active Pharmaceutical Ingredient (API) Market Outlook, Demand, Key Manufacturers by 2025
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Active</strong> <strong>Pharmaceutical</strong> <strong>Ingredient</strong> (<strong>API</strong>) <strong>Market</strong> <strong>Outlook</strong>, <strong>Demand</strong>,<br />
<strong>Key</strong> <strong>Manufacturers</strong> <strong>by</strong> <strong>2025</strong><br />
“The global <strong>Active</strong> <strong>Pharmaceutical</strong> <strong>Ingredient</strong> (<strong>API</strong>) market size<br />
was worth at USD 134.2 billion in the year 2015 which is<br />
anticipated to reach a value of USD 239.8 billion <strong>by</strong> <strong>2025</strong>, with<br />
CAGR of 6.0%. Rising prevalence of chronic diseases such as<br />
neurological diseases.<br />
The global <strong>Active</strong> <strong>Pharmaceutical</strong> <strong>Ingredient</strong> (<strong>API</strong>) market size was worth at USD 134.2 billion in the year 2015<br />
which is anticipated to reach a value of USD 239.8 billion <strong>by</strong> <strong>2025</strong>, with CAGR of 6.0%. Rising prevalence of<br />
chronic diseases such as neurological diseases, cardiovascular diseases, can lead to the growth.<br />
The key drivers can be the rising demand of efficient and rapid acting drugs and introduction of innovative drug<br />
production facility. Major key players are choosing for outsourcing the product from the developing regions<br />
such as India, Brazil and China, which also anticipated to drive the market.<br />
In addition, pharmaceutical companies face tremendous loss in terms of revenue owing to the patent expiration<br />
of blockbuster drugs. Expiration of patent results in increasing focus for development of generic versions of the<br />
molecules. The R&D investment of the company are no longer valuable after patent expiration. Thus, the <strong>API</strong><br />
outsourcing trend in rising.<br />
Synthesis Type Insights<br />
Based on synthesis type, the market is categorized into synthetic and biotech. Various methods are adopted <strong>by</strong><br />
the manufacturing companies depending up on the complexity of the molecule required. Synthetic drugs are<br />
manufactured on the basis of organic chemistry in contrast to biotechnology based drugs, which are produced<br />
<strong>by</strong> utilizing molecular techniques. Further classification of biotech segment is recombinant proteins, monoclonal<br />
antibodies and vaccines.<br />
Request Sample Copy of this <strong>Market</strong> Research @<br />
https://www.millioninsights.com/industry-reports/active-pharmaceutical-ingredients-api-market/request-sample
In 2015, synthetic segment held the largest share. The key factors for the biotech <strong>API</strong>s segment growth are large<br />
R&D investment for new biosimilars, increasing demand for protein-based medicines, and rising focus of key<br />
manufacturers toward biological drugs.<br />
Manufacturer Type Insights<br />
Based on the type of manufacturer, it is categorized into outsourced or merchant or in-house or captive <strong>API</strong>s.<br />
According to market estimates, in 2015, in-house <strong>API</strong>s was the largest segment and outsourced <strong>API</strong>s are<br />
anticipated to be the fastest growing market.<br />
All pharmaceutical companies does not have separate unit for the formulation of <strong>API</strong>. This has led to rise in the<br />
outsourcing of the molecules from the production sites. The need of investment in expensive production<br />
processes is eliminated <strong>by</strong> the outsourcing.<br />
Browse Full Research Report @<br />
https://www.millioninsights.com/industry-reports/active-pharmaceutical-ingredients-api-market<br />
Type Insights<br />
Based on the type, <strong>API</strong>s are classified into innovative and generics. Branded products come under innovative<br />
type, whereas the generic drugs are the ones, which are available OTC (over the counter). Owing of high rate of<br />
prescription, high drug development initiatives, and high price, the innovative <strong>API</strong>s segment dominated in 2015.<br />
Generic segment is anticipated to be fastest-growing type, due to expirations of patents of various blockbuster<br />
drugs. Patent expirations of branded drugs have very serious negative impacts on the drug producers, as the<br />
companies face the tremendous loss after expiration. Hence the drug manufacturers prefer more generic drugs<br />
than the branded ones.<br />
Regional Insights<br />
In 2015, <strong>API</strong> market was dominated <strong>by</strong> the North America and is anticipated to retain its position in upcoming<br />
years owing to encouraging government initiatives for generic drug usage, rising R&D expenditure, and<br />
technological advancements in the drug manufacturing practices.
Asia Pacific is anticipated to be the region with fastest growth owing to the increasing availability of cheap and<br />
affordable labour. Hence, key major companies are setting up their <strong>API</strong> production plants in developing<br />
countries of Asia Pacific such as China and India.<br />
Competitive Insights<br />
One of the key manufacturers of the <strong>API</strong> (<strong>Active</strong> pharmaceutical ingredients) is Teva <strong>Pharmaceutical</strong>s Ltd. Some<br />
of the additional key players in this industry includes Boehringer Ingelheim GmbH, AbbVie, Inc., Merck & Co.,<br />
Inc. and Cipla, Inc., New molecule launches, collaborations, acquisitions, and regional expansions are some<br />
strategic initiatives taken <strong>by</strong> these <strong>Key</strong> players to retain their position.<br />
<strong>Market</strong> Segment:<br />
<strong>API</strong> Type of Synthesis <strong>Outlook</strong> (Revenue, USD Billion, 2014 - <strong>2025</strong>)<br />
• Biotech<br />
• Monoclonal antibodies<br />
• Recombinant proteins<br />
• Vaccines<br />
• Synthetic<br />
<strong>API</strong> Type of Manufacturer <strong>Outlook</strong> (Revenue, USD Billion, 2014 - <strong>2025</strong>)<br />
• Captive <strong>API</strong>s<br />
• Merchant <strong>API</strong>s<br />
<strong>API</strong> Type <strong>Outlook</strong> (Revenue, USD Billion, 2014 - <strong>2025</strong>)<br />
• Generic <strong>API</strong>s<br />
• Innovative <strong>API</strong>s<br />
<strong>API</strong> Application <strong>Outlook</strong> (Revenue, USD Billion, 2014 - <strong>2025</strong>)<br />
• Cardiovascular Disease<br />
• Oncology<br />
• CNS & Neurological Disorders<br />
• Orthopedic Disorders<br />
• Endocrinology<br />
• Pulmonology<br />
• Gastrointestinal Disorders<br />
• Nephrology<br />
• Ophthalmology
<strong>API</strong> Regional <strong>Outlook</strong> (Revenue, USD Billion, 2014 - <strong>2025</strong>)<br />
• North America<br />
• U.S.<br />
• Canada<br />
• Europe<br />
• Germany<br />
• UK<br />
• Asia Pacific<br />
• China<br />
• Japan<br />
• Latin America<br />
• Mexico<br />
• Brazil<br />
• MEA<br />
• South Africa<br />
See More Reports of this Category <strong>by</strong> Million Insights @<br />
https://www.millioninsights.com/industry/pharmaceuticals
Get in touch<br />
At Million Insights, we work with the aim to reach the highest levels of customer satisfaction. Our<br />
representatives strive to understand diverse client requirements and cater to the same with the<br />
most innovative and functional solutions.<br />
Contact Person:<br />
Ryan Manuel<br />
Research Support Specialist, USA<br />
Email: ryan@millioninsights.com<br />
Global Headquarters<br />
Million Insights<br />
Felton Office Plaza 6265 Highway 9 Felton, California 95018, United States<br />
Phone: 1-408-610-2300<br />
Email: sales@millioninsights.com<br />
Asia Pacific<br />
Million Insights<br />
Office No. 302, 3rd Floor, Manikchand Galleria, Model Colony, Shivaji Nagar, Pune, MH, 411016<br />
India<br />
Phone: 91-20-65300184
Change language